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Summary 
Platelet-derived growth factor (PDGF), a potent mitogen for mesenchymal cells in culture, is 
expressed in vivo in a variety of inflammatory conditions associated with cell proliferation,  inchding 
atherosclerosis, wound repair,  pulmonary fibrosis,  and glomerulonephritis. However, it is not 
known if PDGF mediates the fibroproliferative responses that characterize these inflammatory 
disorders. We administered neutralizing anti-PDGF IgG or control IgG to rats with mesangial 
proliferative nephritis. Inhibition of PDGF resulted in a significant reduction in mesangial cell 
proliferation, and largely prevented the increased deposition of extracellular matrix associated 
with the disease. This suggests that PDGF may have a central role in proliferative glomerular disease. 
M 
esangial cell proliferation and matrix expansion char- 
acterize many types of glomerulonephritis (GN). The 
observations that platelet-derived growth factor (PDGF) is 
a potent mitogen for mesangial cells in culture (1) and is ex- 
pressed in both experimental and human GN in which mesan- 
gial cell proliferation occurs (2-5) suggest that this factor may 
have an important role in mediating these changes. 
One model in which PDGF has been studied is the mesan- 
gial proliferative GN in rats induced by antibody to the Thy-1 
antigen, which is expressed by mesangial calls (2). The model 
is characterized by an acute complement-dependent loss of 
mesangial cells  with  disruption  of the mesangial  matrix 
("mesangiolysis") that is maximal at 24 h (2). The mesangial 
cell population, which is almost completely eliminated, un- 
dergoes a rebound proliferation that  is accompanied by a 
marked upregnlation of PDGF A  and B chain mKNA in 
total glomerular RNA at 3 and 5 d after disease induction 
(2). When rats were depleted of tither complement or platdets 
and were injected with anti-Thy-1 antibody, both the glo- 
merular ceU proliferation and increased glomerular PDGF ex- 
pression were significantly inhibited (2, 3). However, despite 
demonstrating a strong association between glomerular PDGF 
expression  and  glomerular cell proliferation in  mesangial 
proliferative GN,  these studies do not determine whether 
PDGF plays a direct role in the pathogenesis of glomerular 
injury. We now report the effect of blocking PDGF in vivo 
in this model of nephritis utilizing a neutralizing polyclonal 
antibody to PDGF. 
Materials  and Methods 
Experimental Protocol.  Anti-Thy-1  GN was induced with goat 
anti-Thy-1 plasma  in 150-200-g male Wistar rats (Simonsen, Gilroy, 
CA) as previously described (2). 8 h before the injection of anti- 
Thy-1 antibody, rats were injected with goat anti-PDGF IgG (60 
mg/100 g body weight, i.p.) (n  =  6) or equivalent quantities of 
nonimmune (control) goat IgG (n = 6) with repeated doses daily 
for 4 d. After disease induction, rats underwent renal biopsies at 
2 and 4 d. Blood samples were collected for serum C3 levels (at 
0, 2, and 4 d), leukocyte and platelet counts (day 4), and plasma 
anti-PDGF IgG levels (day 4, measured by ELISA [6]). 
Anti-PDGFAntibody.  The anti-PDGF IgG was raised in a goat 
immunized with PDGF purified from outdated human platelets 
and specifically  neutralizes the mitogenic activity of rat PDGF and 
all dimeric forms of human PDGF (6). 
Histology.  The following antibodies were used for immuno- 
peroxidase staining of methyl Caruoy's fixed, paraflfin-embedded 
tissue: 19A2 (Coulter Immunology, Hialeah, FL), a mAb to the 
proliferating cell nuclear antigen (PCNA), which is a cell prolifer- 
ation marker; ED-1 (Bioproducts for Science, Indianapolis, IN), 
a mAb to rat monocytes and macrophages; rabbit anti-rat collagen 
I and rabbit anti-rat laminin (Chemicon, Temecula, CA); rabbit 
anti-mouse collagen  IV (Collaborative  Research  Inc., Bedford,  MA); 
rabbit anti-mouse entactin (gift of A. Chung, Pittsburgh,  PA); 
and rabbit  anti-mouse heparan sulfate proteoglycan (gift of J. 
Couchman, Birmingham, AL) (2, 7). Immunofluorescence  of snap- 
frozen tissue was also performed using FITC-conjugated rabbit 
anti-goat IgG and FITC-conjugated goat anti-rat C3 antibodies 
(Organon Teknika Corp.,  West Chester, PA) (8). Histological 
changes were quantitated as previously described (2, 7). PDGF B 
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digoxigenin-labeled antisense cRNA probe and quantitated as pre- 
viously described (3). 
Statistics.  Values are expressed as mean  _+ SD. The one-tailed 
student's t test was used to test the hypothesis  that anti-PDGF treat- 
ment would reduce cell proliferation, total glomerular cellularity, 
or matrix expansion relative to controls. 
Results and Discussion 
In this study, neutralizing anti-PDGF IgG or control IgG 
was administered to rats with mesangial proliferative GN. 
Two time points were selected for study, representing the 
day of initial proliferation (day 2) and the day of peak prolifer- 
ation (day 4). Later time points were not studied due to the 
concern that the rats would develop autoantibodies to  the 
administered goat IgG. 
Anti-PDGF IgG treatment was well tolerated, and serum 
C3 levels (measured at 0, 2, and 4 d) and platelet and leuko- 
cyte counts (at 4 d) were normal and not different from con- 
trols.  Whereas anti-PDGF  IgG levels were undetectable in 
control rats, plasma anti-PDGF IgG levels in treated rats were 
4.6  _+  0.7  mg/ml at day 4,  concentrations that are 20-30 
times that required to inhibit the mitogenic activity of PDGF 
on rat smooth muscle cells in vitro  (6). 
Previous studies have demonstrated that the initial injury 
(i.e.,  mesangiolysis) in this model is dependent on delivery 
and binding of anti-Thy-1  antibody to the mesangial cell fol- 
lowed by complement activation (9). Anti-PDGF IgG treat- 
ment did not prevent this initial injury, as both control and 
anti-PDGF IgG-treated rats had equivalent mesangiolysis (2.6 
_+  0.5 vs. 2.9  +_  0.2, respectively, scale of 0-4+; p  =  NS) 
with an equal reduction in total glomerular cellularity at day 
2 (Table 1). Anti-PDGF IgG treatment also did not inhibit 
the glomerular macrophage infiltration at either day 2 (9.1 
Table  1.  Effect of Anti-PDGF IgG  Treatment on  Total 
Glomerular Cellularity and Proliferating (PCNA +) Cells in 
Mesangial Proliferative GN. 
Proliferating 
Total cells  (PCNA §  cells 
Normal  77  _+  1.8  0.9  _+ 0.2 
Mesangial proliferative GN, day 2 
Control  53  +  5  10.4  _+  1 
Anti-PDGF  53  _+ 6  10.0  _+  2 
Mesangial proliferative GN,  day 4 
Control  89  +_  13  13.4  _+  4 
Anti-PDGF  77  +  10"  5.7  _+  1~ 
Values are expressed as the mean number  _+  SD of cells per glomerular 
cross-section.  For comparison,  values for  normal  Wistar  rats  (n  =  6) 
are  shown  (2). 
* p  <(0.05  relative to control  rats. 
* p  <0.005  relative to  control  rats. 
Figure 1.  Compared with control rats with mesangial proliferative GN 
(a),  anti-PDGF  IgG-treated rats with GN  (b) had significantly less glo- 
merular cellularity at day 4  (periodic acid/Schiff reagent with hematox- 
ylin counterstain,  x240). 
+  2 vs.  9.2  _+  1) or day 4  (8.0  +_  2 vs.  8.8  +_  1 ED-1 § 
cells/glomerular cross-section in control vs. anti-PDGF IgG- 
treated rats,  respectively). 
Effect on Glomerular Cell Proliferation.  The initial glomer- 
ular cell proliferation (i.e.,  PCNA + ceils)  was not affected 
by anti-PDGF IgG treatment (Table 1). In contrast, at day 
4, during the peak phase of cell proliferation, a 57% reduc- 
tion in cell proliferation was observed (p <  0.005),  and was 
associated  with a significant reduction in total glomerular 
cellularity as compared with controls (Table  1 and Fig.  1). 
Most of the proliferating cells in this model have been shown 
to be mesangial cells (2,  8),  and this was supported in the 
current study in which >85%  of the PCNA + cells in both 
groups excluded the monocyte-macrophage marker, ED-1, 
by double immunolabeling. 
One concern was that anti-PDGF IgG treatment might 
result in significant PDGF/anti-PDGF  immune complexes 
in glomeruli that would prolong the mesangiolysis and delay 
the proliferative response. However, both control and anti- 
PDGF IgG-treated rats had equivalent mesangial staining of 
IgG at 2 and 4 d (2+, scale of 0-4+) with negative staining 
of C3 by immunofluorescence. Similarly, incubation of both 
resting and proliferating mesangial cells in culture with anti- 
PDGF IgG (5 mg/ml) resulted in no significant 51Cr release 
compared with control IgG in the presence of complement 
(data not shown).  Finally,  injection of equivalent doses of 
anti-PDGF IgG into normal rats (n  =  2) as used in the ex- 
perimental study resulted in no detectable mesangial injury 
in biopsies  obtained at days 2  and 4. 
The observation that mesangial cell proliferation was re- 
duced by anti-PDGF IgG treatment at day 4 but not at day 
2 has several potential interpretations, including: (a) the pos- 
sibility that numerous growth factors, including PDGF, are 
involved in the initial cell proliferation such that mesangial 
cells are maximally stimulated even when PDGF is inhibited; 
(b) the possibility that inadequate anti-PDGF IgG was present 
locally to block PDGF before its binding to the mesangial 
cell at day 2;  and (c) the possibility that responsiveness to 
PDGF requires upregulation of the PDGF receptor. PDGF 
receptor B subunit expression is known to be upregulated 
in this disease (2), and in this study, PDGF receptor/~ subunit 
immunostaining was markedly increased in glomeruli at day 
4  relative to  day 2  (data not shown). 
Other possible  growth regulatory molecules that could 
mediate the initial mesangial cell proliferation include factors 
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diffuse in glomeruli of control rats with mesangial proliferative GN (a), 
in anti-PDGF IgG-treated rats with GN, expression was often segmental 
(b). Hybridization with a sense probe for PDGF B chain mRNA was always 
negative  (c) ( x 240). 
released by platelets, since thrombocytopenic animals show 
a decrease in mesangial cell proliferation in this model at day 
3  (8)  and basic fibroblast  growth factor (bFGF),  which is 
released by  a  variety  of damaged cells,  and  is  a  mitogen 
for mesangial cells in culture (10). Recently, we have shown 
that mesangial cells produce bFGF, and release bFGF during 
acute mesangiolysis (i.e., the first 24 h) in this model (J. Floege 
et al., manuscript submitted for publication). This may also 
be relevant to the PDGF-mediated response, given that bFGF 
will induce both PDGF expression by mesangial cells in cul- 
ture (10) and an increase in PDGF receptors on smooth muscle 
cells (our unpublished observations). 
Glomerular Source of  PDGE  Although the source of the 
glomerular PDGF may partially originate from platelets, ac- 
tivated macrophages, or endothelial cells, our previous studies 
(2, 3) suggest that most of the PDGF is expressed by mesan- 
gial cells, where it may function as an autocrine growth factor. 
Table  2.  Effect  of Anti-PDGF IgG Treatment on Extracellular 
Matrix Accumulation in Mesangial Proliferative GN 
Normal  Control  Anti-PDGF 
Type  IV collagen  0.9  +  0.8  3.1  _+  0.7  2.1  +  0.4* 
Type  I  collagen  0.03  _+  0.02  2.5  _+  0.6  1.6  _+  0.4* 
Laminin  0.8  +  0.4  2.6  _+ 0.6  1.8  +  0.3* 
Entactin/nidogen  0.2  _+ 0.1  2.5  _+ 0.7  1.6  _+ 0.4* 
Heparan  sulfate 
proteoglycan  1.8  _+ 0.5  3.1  +_ 0.6  2.6  +_ 0.6 
Semiquantitative  immunohistochemical  scores for various ECM compo- 
nents (scale of 0-4 +  [7]) in the mesangium of rats with mesangial prolifer- 
ative GN that had been treated  with nonimmune IgG (control, n  =  6) 
or with anti-PDGF IgG (n  =  6). For comparison,  the values in normal 
Wistar rats  (n  =  6) are  shown. 
* p  <0.01  vs.  control rats. 
Figure 3.  A diffuse increase in laminin was present in the mesangium 
of control rats with GN (a), and was significantly  reduced in rats with 
GN that  had  received anti-PDGF IgG (b)  (x240). 
We therefore performed in situ hybridization to determine 
the effect of anti-PDGF  IgG treatment  on PDGF  B  chain 
mRNA expression at day 4. An increase in PDGF B chain 
mKNA could be detected in mesangial regions in both con- 
trol and anti-PDGF IgG-treated rats (Fig. 2). However, the 
amount of PDGF B chain mRNA in the glomeruli was lower 
in anti-PDGF IgG-treated animals (1.68  _+ 0.4 vs. 1.24 +  0.2 
in control vs. anti-PDGF-treated rats, scale of 0-3+, one-tailed 
Student's t test; p  ~0.05  [3]).  The reduction in glomerular 
expression  of PDGF  B  chain  mRNA  in  the  anti-PDGF 
IgG-treated  rats is consistent with an inhibition of mesan- 
gial cell proliferation and an interruption of PDGF-mediated 
induction of its  own expression in mesangial cells (10). 
Effect of  Anti-PDGF IgG Treatment  on Extracellular  Matrix 
(ECM) Accumulation.  Previous studies have demonstrated that 
in this model mesangial cell proliferation is accompanied by 
an expansion of several ECM proteins in the mesangium (7, 
11). In this study, control rats with anti-Thy-1 GN also had 
a diffuse increase in glomerular staining at day 4 for various 
ECM proteins, including types I and IV collagen, laminin, 
and entactin (Table 2), In contrast, glomeruli from anfi-PDGF 
IgG--treated rats with GN showed significantly less, and often 
only segmental, increases in  staining (Table 2  and Fig.  3). 
The reduction in immunostaining for the various ECM 
components in anti-PDGF  IgG-treated  rats may reflect, in 
part, the reduction in mesangial cell number. Alternatively, 
anti-PDGF  treatment  may be affecting TGF-~/production 
within the glomeruli. PDGF induces mesangial cells to ex- 
press TGF-3  (12).  TGF-3,  in turn,  induces mesangial cells 
to produce a variety of ECM components (13,  14).  TGF-~ 
is  also increased in glomeruli of rats with  anti-Thy-1 GN, 
and treatment of rats with anti-Thy-1 GN with anti-TGF-fl 
antibody inhibits expansion of the mesangial matrix (11). Thus, 
it is possible that the beneficial effects of anti-PDGF  treat- 
ment on ECM expansion in anti-Thy-1 GN may reflect inhi- 
bition of PDGF-mediated stimulation of mesangial cell produc- 
tion of TGF-3. 
In conclusion, the current  study provides the first direct 
in vivo evidence for a role for PDGF as a growth stimulatory 
molecule in GN. Treatment of rats with mesangial prolifera- 
tive GN with a neutralizing anti-PDGF antibody significantly 
reduced mesangial cell proliferation and matrix expansion at 
4 d. The observation that the inhibition was only partial (i.e., 
60%)  suggests that  other  growth factors may be involved 
in this proliferative response, or that there was insufficient 
antibody available at the cellular level to effect a total response. 
1415  Johnson et al.  Brief Definitive Report The fact that this degree of proliferation and matrix expan- 
sion could be reduced by inhibiting  a single growth factor 
suggests that  PDGF may play a crucial role in progressive 
glomerular  injury. 
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